Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada

6 Sept 2025

Abstract excerpt

For some of the COVID-19 vaccines, the drug substances released to market were manufactured differently than those used in clinical trials. Manufacturing nucleoside-modified mRNA (modRNA) for commercial COVID-19 vaccines relies on RNA polymerase transcription of a plasmid DNA template. Previous studies identified high levels of plasmid DNA in vials of modRNA vaccines, suggesting that the removal of residual DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to RNA Interference and Gene Delivery
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40913499
DOI: 10.1080/08916934.2025.2551517

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, CanadaPMID 40913499Read ↗

Residual DNA impurities in AAV vectors—nature and transcriptionSemantic proximity Read ↗

A Brief Review on Dna Vaccines in the Era of COVID-19Semantic proximity Read ↗

Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease IndicationsSemantic proximity Read ↗

The EMA covid-19 data leak, and what it tells us about mRNA instabilitySemantic proximity Read ↗

Precision DNA Impurity Reduction Approaches for Ultra-Pure rAAV ManufacturingSemantic proximity Read ↗

Technical and regulatory hurdles for DNA vaccinesSemantic proximity Read ↗

Stowaways in the cargo: Contaminating nucleic acids in rAAV preparations for gene therapySemantic proximity Read ↗

Regulatory Assessment Gaps and Genotoxicity Considerations in mRNA-LNP TechnologiesSemantic proximity Read ↗

Vector Design for Improved DNA Vaccine Efficacy, Safety and ProductionSemantic proximity Read ↗

mRNA: vaccine or gene therapy? The safety regulatory issuesSemantic proximity Read ↗

Detection and Characterization of Pestivirus Contaminations in Human Live Viral VaccinesSemantic proximity Read ↗

The Platform Technology Approach to mRNA Product Development and RegulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.